收藏切换
The discussion on a proposed quality similarity assessment criteria of rituximab biosimilar
收藏切换
PDF
Bo-ning LIU, Hong-jin KAN, Yu BAI*, Jian-hui LUO*
Acta Pharmaceutica Sinica | 2019, 54(11) : 2118 - 2125
Less
收藏切换
Acta Pharmaceutica Sinica | 2019, 54(11): 2118-2125
New Drug Forum
The discussion on a proposed quality similarity assessment criteria of rituximab biosimilar
Full
Bo-ning LIU, Hong-jin KAN, Yu BAI*, Jian-hui LUO*
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
Published: 2019-11-12 doi: 10.16438/j.0513-4870.2019-0477
Outline
收藏切换

Recently, biosimilar antibodies have become a mainstream component of the biopharmaceutical industry in China. The principle requirements for the development and evaluation of biosimilars are based on proving similarity in product quality (analytical similarity) between a proposed biosimilar candidate and the originator reference drug. However, because the quality of a reference drug often varies during the life cycle and not all reference drug samples are able to collected by a biosimilar sponsor, it has not been practical to accurately determine the critical quality attributes as well as an accurate control range through the characterization of the limited number of reference drug lots that are typically collected. Therefore, the development and evaluation of biosimilars has been challenging both for industry and regulatory agencies. In this article, The Chemistry, Manufacturing and Control (CMC) dossier of the rituximab originator company and the dossiers of 18 biosimilar companieswere retrospectively analyzed. Furthermore, the assessment criteria to determine quality similarity of rituximab biosimilar candidates have been proposed, which criteria have been used by reviewing the physicochemical and biological properties data obtained from 123 lots of the reference drug. Moreover, some case studies have been provided that illustrate the application of the proposed analytical similarity criteria in the practice of drug evaluation.

rituximab  /  biosimilar  /  quality similarity  /  analytical similarity  /  chemistry manufacturing controls review  /  critical quality attribute
Bo-ning LIU, Hong-jin KAN, Yu BAI, Jian-hui LUO. The discussion on a proposed quality similarity assessment criteria of rituximab biosimilar[J]. Acta Pharmaceutica Sinica, 2019 , 54 (11) : 2118 -2125 . DOI: 10.16438/j.0513-4870.2019-0477
Year 2019 volume 54 Issue 11
PDF
212
91
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2019-0477
  • Receive Date:2019-06-15
  • Online Date:2026-01-26
  • Published:2019-11-12
Article Data
Affiliations
History
  • Received:2019-06-15
  • Revised:2019-08-12
Funding
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2019-0477
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT